Pharmesis Intl - Change - Announcement of Appointment::Appointment of Executive Chairman
Announcement Type: Announcement of Appointment
Company: PHARMESIS INTERNATIONAL LTD.
Stock Code/Name: P31 - Pharmesis Intl
Company: PHARMESIS INTERNATIONAL LTD.
Stock Code/Name: P31 - Pharmesis Intl
| Change - Announcement of Appointment::Appointment of Executive Chairman |
| Issuer & Securities |
| Issuer/ Manager | PHARMESIS INTERNATIONAL LTD. |
| Securities | PHARMESIS INTERNATIONAL LTD. - SG1Q12920787 - P31 |
| Stapled Security | No |
| Announcement Details |
| Announcement Title | Change - Announcement of Appointment |
| Date & Time of Broadcast | 15-Jan-2015 17:26:35 |
| Status | New |
| Announcement Sub Title | Appointment of Executive Chairman |
| Announcement Reference | SG150115OTHRQ05C |
| Submitted By (Co./ Ind. Name) | Mr Wu Xuedan |
| Designation | Executive Director / Chief Executive Officer |
| Description (Please provide a detailed description of the event in the box below) | Appointment of Mr Jiang Yun as the Executive Chairman of Pharmesis International Ltd. ("Company") |
| Additional Details |
| Date Of Appointment | 15/01/2015 |
| Name Of Person | Jiang Yun |
| Age | 53 |
| Country Of Principal Residence | China |
| The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process) | The Board considered the nominating committee's recommendation and assessment of Mr Jiang Yun's background, qualifications and experience and is satisfied with the value that he can contribute to the board. |
| Whether appointment is executive, and if so, the area of responsibility | Yes, Responsible for the strategic direction of the Group. |
| Job Title (e.g. Lead ID, AC Chairman, AC Member etc.) | (a) Executive Chairman; and (b) Member of Nominating Committee |
| Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries | Yes |
| Conflict of interests (including any competing business) | No |
| Working experience and occupation(s) during the past 10 years | Sichuan Neautus Traditional Chinese Medicine Co., Ltd. - CEO and Executive Chairman of Board (March 2005 - Present) Pharmesis International Ltd. - Executive Director and Executive Chairman of Board (October 2004 - January 2009) |
| Shareholding interest in the listed issuer and its subsidiaries? | Yes |
| Shareholding Details | Mr Jiang Yun is deemed interested in the 49% shareholding in the Company's indirect subsidiary, Sichuan Longlife Pharmaceutical Co., Ltd |
| # These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8). | |
| Past (for the last 5 years) | Sichuan Neautus Traditional Chinese Medicine Co., Ltd. |
| Present | Sichuan Neautus Traditional Chinese Medicine Co., Ltd. |
| (a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner? | No |
| (b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency? | No |
| (c) Whether there is any unsatisfied judgment against him? | No |
| (d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose? | No |
| (e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach? | No |
| (f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part? | No |
| (g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust? | No |
| (h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust? | No |
| (i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity? | No |
| (i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or | No |
| (ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or | No |
| (iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or | No |
| (iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust? | No |
| (k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere? | No |
| Any prior experience as a director of a listed company? | Yes |
| If Yes, Please provide details of prior experience | Pharmesis International Ltd. - Executive Director and Executive Chairman of Board (October 2004 - January 2009) |
Pharmesis Intl - General Announcement::Changes in the Composition of the Board and Board Committees
Announcement Type: General Announcement
Company: PHARMESIS INTERNATIONAL LTD.
Stock Code/Name: P31 - Pharmesis Intl
Company: PHARMESIS INTERNATIONAL LTD.
Stock Code/Name: P31 - Pharmesis Intl
| General Announcement::Changes in the Composition of the Board and Board Committees |
| Issuer & Securities |
| Issuer/ Manager | PHARMESIS INTERNATIONAL LTD. |
| Securities | PHARMESIS INTERNATIONAL LTD. - SG1Q12920787 - P31 |
| Stapled Security | No |
| Announcement Details |
| Announcement Title | General Announcement |
| Date & Time of Broadcast | 15-Jan-2015 17:25:28 |
| Status | New |
| Announcement Sub Title | Changes in the Composition of the Board and Board Committees |
| Announcement Reference | SG150115OTHRYU6B |
| Submitted By (Co./ Ind. Name) | Mr Wu Xuedan |
| Designation | Executive Director / Chief Executive Officer |
| Description (Please provide a detailed description of the event in the box below) | Please refer to the attachment. |
| Attachments |
IHH - General Announcement::NOTICE OF CHANGE IN DIRECTORS INTEREST PURSUANT TO SECTION 135 OF THE COMPANIES ACT, 1965
Announcement Type: General Announcement
Company: IHH HEALTHCARE BERHAD
Stock Code/Name: Q0F - IHH
Company: IHH HEALTHCARE BERHAD
Stock Code/Name: Q0F - IHH
| General Announcement::NOTICE OF CHANGE IN DIRECTORS INTEREST PURSUANT TO SECTION 135 OF THE COMPANIES ACT, 1965 |
| Issuer & Securities |
| Issuer/ Manager | IHH HEALTHCARE BERHAD |
| Securities | IHH HEALTHCARE BERHAD - MYL5225OO007 - Q0F |
| Stapled Security | No |
| Announcement Details |
| Announcement Title | General Announcement |
| Date & Time of Broadcast | 15-Jan-2015 17:36:09 |
| Status | New |
| Announcement Sub Title | NOTICE OF CHANGE IN DIRECTORS INTEREST PURSUANT TO SECTION 135 OF THE COMPANIES ACT, 1965 |
| Announcement Reference | SG150115OTHR3AC5 |
| Submitted By (Co./ Ind. Name) | SEOW CHING VOON |
| Designation | COMPANY SECRETARY |
| Description (Please provide a detailed description of the event in the box below) | The attached announcement was made on Bursa Malaysia Securities Berhad on 15 January 2015. |
| Attachments |
IHH - General Announcement
Announcement Type: General Announcement
Company: IHH HEALTHCARE BERHAD
Stock Code/Name: Q0F - IHH
Company: IHH HEALTHCARE BERHAD
Stock Code/Name: Q0F - IHH
| General Announcement::DEALINGS IN LISTED SECURITIES (CHAPTER 14 OF LISTING REQUIREMENTS) : DEALINGS OUTSIDE CLOSED PERIOD |
| Issuer & Securities |
| Issuer/ Manager | IHH HEALTHCARE BERHAD |
| Securities | IHH HEALTHCARE BERHAD - MYL5225OO007 - Q0F |
| Stapled Security | No |
| Announcement Details |
| Announcement Title | General Announcement |
| Date & Time of Broadcast | 15-Jan-2015 17:34:33 |
| Status | New |
| Announcement Sub Title | DEALINGS IN LISTED SECURITIES (CHAPTER 14 OF LISTING REQUIREMENTS) : DEALINGS OUTSIDE CLOSED PERIOD |
| Announcement Reference | SG150115OTHR9WJ7 |
| Submitted By (Co./ Ind. Name) | SEOW CHING VOON |
| Designation | COMPANY SECRETARY |
| Description (Please provide a detailed description of the event in the box below) | The attached announcement was made on Bursa Malaysia Securities Berhad on 15 January 2015. |
| Attachments |
G Invacom - Share Buy Back - Daily Share Buy-Back Notice::Share Buy-Back of 1,000,000 Ordinary Shares on 15 January 2015
Announcement Type: Share Buy Back-On Market
Company: GLOBAL INVACOM GROUP LIMITED
Stock Code/Name: QS9 - G Invacom
Company: GLOBAL INVACOM GROUP LIMITED
Stock Code/Name: QS9 - G Invacom
| Share Buy Back - Daily Share Buy-Back Notice::Share Buy-Back of 1,000,000 Ordinary Shares on 15 January 2015 |
| Issuer & Securities |
| Issuer/ Manager | GLOBAL INVACOM GROUP LIMITED |
| Securities | GLOBAL INVACOM GROUP LIMITED - SG2E91982768 - QS9 |
| Stapled Security | No |
| Announcement Details |
| Announcement Title | Share Buy Back - Daily Share Buy-Back Notice |
| Date & Time of Broadcast | 15-Jan-2015 17:08:11 |
| Status | New |
| Announcement Sub Title | Share Buy-Back of 1,000,000 Ordinary Shares on 15 January 2015 |
| Announcement Reference | SG150115OTHRCV2K |
| Submitted By (Co./ Ind. Name) | Anthony Brian Taylor |
| Designation | Executive Chairman |
| Description (Please provide a detailed description of the event in the box below) | Daily share buy-back by way of market acquisition. |
| Additional Details |
| Start date for mandate of daily share buy-back | 30/04/2014 |
| Section A |
| Name of Overseas exchange where company has dual listing | AIM of London Stock Exchange | |||||||||||||||
| Maximum number of shares authorised for purchase | 23,180,230 | |||||||||||||||
| Purchase made by way of market acquisition | Yes | |||||||||||||||
| ||||||||||||||||
| Price Paid per share | ||||||||||||||||
| ||||||||||||||||
| Section B |
| Purchase made by way of off-market acquisition on equal access scheme | No |
| Section C |
| |||||||||||||
| #Percentage of company's issued shares excluding treasury shares as at the date of the share buy-back resolution | |||||||||||||
| ^From the date on which share buy-back mandate is obtained | |||||||||||||
| Section D |
| Number of issued shares excluding treasury shares after purchase | 264,099,299 |
| Number of treasury shares held after purchase | 18,303,000 |
No comments:
Post a Comment